The Latest Breaking News from Moderna

Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine

Roughly 29 million people are eligible for an autumn booster but there are just 13 million doses of the new bivalent Moderna jab available

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

The prime minister has made claims Australia must be more self-reliant.

The total number of COVID-19 cases identified in Australia since the start of the pandemic is closing in on 10 million.

An Omicron-specific booster vaccination has been approved in the UK

Moderna, Inc (NASDAQ: MRNA) spiked up almost 5% off Friday’s closing price at one point on Monday, before hitting a resistance level at the $179 level and running into a group of sellers. 

Adults over 50 and clinically vulnerable people will be offered the first Covid-19 jab to target two strains of the virus, as part of the UK’s autumn booster programme.

Health Secretary Steve Barclay has said the vaccine will be part of the autumn booster programme.